|Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry|
|Gao, Run-lin1,2; Xu, Bo1,2; Lu, Shu-zheng3; Chen, Ji-lin1,2; Han, Ya-ling; Chen, Jun-zhu4; Gai, Lu-yue; Ge, Jun-bo5; Wang, Wei-min6; Du, Zhi-min; Huo, Yong7; Wang, Le-feng8; Gao, Wei9; Chen, Ji-yan10; He, Ben11; Jia, Guo-liang; Yang, Zhi-jian; Cao, Ke-jiang12; Li, Wei-min13; Shen, Wei-feng14; Wan, Zheng15; Huang, De-jia16; Zhu, Guo-ying17; CCSR Investigators|
|关键词||registry drug-eluting stent Sirolimus-eluting stent|
|刊名||INTERNATIONAL JOURNAL OF CARDIOLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Cardiac & Cardiovascular Systems|
|研究领域[WOS]||Cardiovascular System & Cardiology|
|关键词[WOS]||RANDOMIZED CONTROLLED-TRIAL ; NATIVE CORONARY-ARTERIES ; BARE-METAL ; IMPLANTATION ; PACLITAXEL ; RESTENOSIS ; THROMBOSIS ; LESIONS ; REVASCULARIZATION ; PREDICTORS|
Objective: This post-marketing surveillance registry is aimed at determining the safety and reliability of the CYPHER Select Sirolimus-eluting stent (SES) in routine clinical practice.
Background: Little information and angiographic follow-up data in large-scale "real world" registry is available for the CYPHER Select SES, an advanced-generation SES.
Methods: This was a prospective multicenter (20 centers) registry. 1189 consecutive patients who received at least 1 CYPHER Select SES during daily clinical practice were enrolled. Patients who underwent emergency stenting for acute myocardial infarction were excluded.
Results: The procedure′s success rate was 98.3% for CYPHER Select SES implantation, and follow-up rates were 98% with 100% data auditing. Target lesion revascularization (TLR) at 12 months occurred in 60 (5.14%) cases, cardiac death in 13 cases (1.11%), Q wave myocardial infarction (MI) in 5 cases (0.43%), non-Q-MI in 9 cases (0.77%), target vessel revascularization (TVR) in 67 cases (5.74%), and MACE defined as cardiac death, nonfatal MI and TLR in 76 cases (6.51%). MACE-free survival rate at 12 months was 93.7%. Angiographic follow-up at 9 months was performed in 418 (68.3%) lesions treated by CYPHER Select SES. The binary restenosis rate was 4.8% in-stent and 9.6% in-segment. Subgroup analysis showed diabetes, bifurcation lesion and combined use of different stents were independent risk factors of cumulative MACE. In-segment MLD <= 2.25 mm at post-procedure and ostial lesion was independent predictors of in-segment restenosis.
Conclusions: In this registry, the MACE, TLR, angiographic late loss and binary restenosis rates of CYPHER Select SES were similar to those reported in SES randomized trials and "real world" registries. The safety and efficacy of CYPHER Select SES shown in this registry are consistent with those seen in SES studies. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
|作者单位||1.Peking Univ, Hosp 1, Beijing, Peoples R China|
2.Beijing Red Cross Chaoyang Hosp, Beijing, Peoples R China
3.Peking Univ, Hosp 3, Beijing, Peoples R China
4.Shanghai Renji Hosp, Shanghai, Peoples R China
5.Jiangsu Prov Peoples Hosp, Jiangsu, Peoples R China
6.Haerbin Univ Med Sci, Affiliated Hosp 1, Harbin, Peoples R China
7.Shanghai Ruijin Hosp, Shanghai, Peoples R China
8.Tianjin Univ Med Sci, Gen Hosp, Tianjin, Peoples R China
9.Sichuan Univ, Hosp 1, Chengdu, Peoples R China
10.Wu Han Asian Heart Hosp, Wuhan, Peoples R China
11.Beijing An Zhen Hosp, Beijing, Peoples R China
12.Fudan Univ, Shanghai Zhongshan Hosp, Shanghai, Peoples R China
13.Peking Univ, Peoples Hosp, Beijing, Peoples R China
14.Chinese Acad Med Sci, Peking Union Med Coll, Cardivasc Inst, Beijing 100037, Peoples R China
15.Chinese Acad Med Sci, Peking Union Med Coll, Fu Wai Hosp, Beijing 100037, Peoples R China
16.Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
17.Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China
|Gao, Run-lin,Xu, Bo,Lu, Shu-zheng,et al. Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY,2008,125(3):339-346.|
|APA||Gao, Run-lin.,Xu, Bo.,Lu, Shu-zheng.,Chen, Ji-lin.,Han, Ya-ling.,...&CCSR Investigators.(2008).Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry.INTERNATIONAL JOURNAL OF CARDIOLOGY,125(3),339-346.|
|MLA||Gao, Run-lin,et al."Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry".INTERNATIONAL JOURNAL OF CARDIOLOGY 125.3(2008):339-346.|